BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3367 related articles for article (PubMed ID: 7520681)

  • 21. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
    Kaufmann R; Spieth K; Leiter U; Mauch C; von den Driesch P; Vogt T; Linse R; Tilgen W; Schadendorf D; Becker JC; Sebastian G; Krengel S; Kretschmer L; Garbe C; Dummer R;
    J Clin Oncol; 2005 Dec; 23(35):9001-7. PubMed ID: 16260697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dacarbazine and interferon-alpha 2a in advanced malignant melanoma: high response rate and prolongation of response duration occur in different patient subpopulations.
    Betticher DC; Lee SM; Morris C; Clemons M; Thatcher N
    Melanoma Res; 1995 Aug; 5(4):277-82. PubMed ID: 7496165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
    Mulder NH; van der Graaf WT; Willemse PH; Koops HS; de Vries EG; Sleijfer DT
    Br J Cancer; 1994 Oct; 70(4):681-3. PubMed ID: 7522510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.
    Falkson CI; Ibrahim J; Kirkwood JM; Coates AS; Atkins MB; Blum RH
    J Clin Oncol; 1998 May; 16(5):1743-51. PubMed ID: 9586887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.
    Hauschild A; Dummer R; Ugurel S; Kaehler KC; Egberts F; Fink W; Both-Skalsky J; Laetsch B; Schadendorf D
    Cancer; 2008 Sep; 113(6):1404-11. PubMed ID: 18615619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant interferon alpha-2a in combination with dacarbazine in the treatment of metastatic malignant melanoma: analysis of long-term responding patients.
    Ron IG; Inbar MJ; Gutman M; Merimsky O; Chaitchik S
    Cancer Immunol Immunother; 1993 Jul; 37(1):61-6. PubMed ID: 8513453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma.
    Comella P; Daponte A; Casaretti R; Ionna F; Fiore F; Presutti F; Frasci G; Caponigro F; Gravina A; Parziale AP; Mozzillo N; Comella G
    Eur J Cancer; 1997 Jul; 33(8):1326-9. PubMed ID: 9301463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
    Papadopoulos NE; Bedikian A; Ring S; Kim KB; Hwu WJ; Gerber DL; Homsi J; Hwu P
    Am J Clin Oncol; 2009 Oct; 32(5):509-14. PubMed ID: 19506454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.
    Falkson CI
    Med Oncol; 1995 Mar; 12(1):35-40. PubMed ID: 8542245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of AMSA alone and in combination with DTIC in patients with metastatic melanoma.
    Polyzos A; Legha SS; Burgess AM; Benjamin RS; Bodey GP
    Invest New Drugs; 1988 Apr; 6(1):57-61. PubMed ID: 3410667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: implications for the treatment of patients with metastatic melanoma.
    Eton O; Talpaz M; Lee KH; Rothberg JM; Brell JM; Benjamin RS
    Cancer; 1996 Mar; 77(5):893-9. PubMed ID: 8608480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma.
    Young AM; Marsden J; Goodman A; Burton A; Dunn JA
    Clin Oncol (R Coll Radiol); 2001; 13(6):458-65. PubMed ID: 11824887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF.
    Bottoni U; Bonaccorsi P; Devirgiliis V; Panasiti V; Borroni RG; Trasimeni G; Clerico R; Calvieri S
    Jpn J Clin Oncol; 2005 Sep; 35(9):507-13. PubMed ID: 16120623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.
    Mulder NH; Willemse PH; Schraffordt Koops H; de Vries EG; Sleijfer DT
    Br J Cancer; 1990 Dec; 62(6):1006-7. PubMed ID: 2257203
    [No Abstract]   [Full Text] [Related]  

  • 35. Dacarbazine and interferon alpha for stage IV malignant melanoma.
    Tamm I; Grimme H; Bergen E; Simon JC; Schöpf E; Mertelsmann R; Lindemann A; Brennscheidt U
    Oncology; 1997; 54(4):270-4. PubMed ID: 9216849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of interferon alfa-2a and dacarbazine in advanced melanoma. Biological Response Modifiers in Melanoma (BREMIM) Italian Cooperative Group.
    Eur J Cancer; 1992; 28A(10):1719-20. PubMed ID: 1389493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.
    Middleton M; Hauschild A; Thomson D; Anderson R; Burdette-Radoux S; Gehlsen K; Hellstrand K; Naredi P
    Ann Oncol; 2007 Oct; 18(10):1691-7. PubMed ID: 17709802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A feasibility study using polychemotherapy (cisplatin + vindesine + dacarbazine) plus interferon-alpha or monochemotherapy with dacarbazine plus interferon-alpha in metastatic melanoma.
    Bajetta E; Del Vecchio M; Vitali M; Martinetti A; Ferrari L; Queirolo P; Sertoli MR; Cainelli T; Cellerino R; Cascinelli N
    Tumori; 2001; 87(4):219-22. PubMed ID: 11693798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoimmunohormonal therapy with carmustine, dacarbazine, cisplatin, tamoxifen, and interferon for metastatic melanoma: a prospective phase II study.
    Stein ME; Bernstein Z; Tsalic M; Drumea K; Steiner M; Sklar Z; Haim N
    Am J Clin Oncol; 2002 Oct; 25(5):460-3. PubMed ID: 12393984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study.
    Shiloni E; Pouillart P; Janssens J; Splinter T; Di Peri T; Symann M; Roest GJ; Palmer PA; Franks CR
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S45-9. PubMed ID: 2697579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 169.